Nurulimab Biosimilar - Research Grade

Human

CTLA4

>1mg/ml

IgG1 - kappa

CHO Cells

Ipilimumab Biosimilar - Research Grade (ICH4025), Tremelimumab Biosimilar - Research Grade (ICH5184), Botensilimab Biosimilar - Research Grade (ICH5412), Evalstotug Biosimilar - Research Grade (ICH5538), Firastotug Biosimilar - Research Grade (ICH5550), Gotistobart Biosimilar - Research Grade (ICH5583), Muzastotug Biosimilar - Research Grade (ICH5696), Quavonlimab Biosimilar - Research Grade (ICH5794), Sovipostobart Biosimilar - Research Grade (ICH5879), Tazlestobart Biosimilar - Research Grade (ICH5904), Tuvonralimab Biosimilar - Research Grade (ICH5951), Vilastobart Biosimilar - Research Grade (ICH5979), Zalifrelimab Biosimilar - Research Grade (ICH5998)

https://www.imgt.org/mAb-DB/

ICH3002

P16410

Blue ice

This product is a research-grade, unconjugated recombinant analog of nurulimab, an anti-CTLA-4 (CD152) monoclonal antibody, offered strictly for research use only. It is a non-therapeutic biosimilar built around the human CTLA-4 target and is not the clinical drug; it is not intended for human or veterinary use. The recombinant human IgG1/kappa format reproduces the target-binding behavior of the originator, making it useful as a reference and control reagent in checkpoint-biology workflows. Typical research applications include in-vitro binding and blocking assays, immune-checkpoint signaling studies, ADCC/effector-function characterization, antibody-engineering and biosimilarity comparisons, and use as a positive control or benchmarking standard alongside other anti-CTLA-4 tools. It is supplied at research-grade low endotoxin (<1 EU/mg), with an ultra-low endotoxin option (<0.5 EU/mg) and in-vivo-standard grades available, and can be provided in bulk milligram-to-gram quantities to support screening, assay development, and preclinical model work. Because the target is human CTLA-4, cross-reactivity and model selection should be confirmed empirically for each experimental system. CTLA-4 (CD152; UniProt P16410) is an inhibitory immune-checkpoint receptor of the immunoglobulin superfamily, expressed on activated conventional T cells and constitutively on regulatory T cells (Tregs). It shares the B7 ligands CD80 and CD86 with the co-stimulatory receptor CD28 but binds them with markedly higher avidity, thereby outcompeting CD28 and dampening the co-stimulatory signal required for full T-cell activation. CTLA-4 also physically removes CD80/CD86 from antigen-presenting cells by trans-endocytosis and recruits phosphatases that attenuate TCR signaling. Through these mechanisms it enforces peripheral tolerance and restrains excessive T-cell responses. Blocking CTLA-4 lowers the activation threshold and enhances T-cell priming and effector function, which is the rationale behind checkpoint-blockade approaches in tumor immunology.

Cytotoxic T-lymphocyte-associated antigen 4, Cytotoxic T-lymphocyte protein 4, CD152

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks